Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by serendipidyon Jan 17, 2019 7:15am

96 Views

Post# 29244036

RE:RE:RE:RE:What is the volatility going to fluctuat to?

FYI - Salzman is NOT a partner, they are in a contract position with Kaly conducting our Phase 2 clinical trials. They agreed to be paid monthly by shares, which must be sold each and every month, stipulation of the contract.. Regarding echelon, and their #''s , that poster is not giving the whole picture re current and expected price either. If you put kaly there it would say current 9.5 expected .30, but note that expectation is from a yr from now. One must look at the complete puzzle, not just the border.. review the contract, the case studies, the success of them, the fda path, the patents, graft vs host, gw pharma, cbd's, and then lets speak...

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale